UK tribunal upholds CMA pharmaceutical excessive pricing decision
The UK’s antitrust enforcer was correct to penalise Advanz and its two former parent companies for hiking the price of a thyroid drug by 1,110%, the country’s specialist competition tribunal has ruled.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.